Gilead Sciences Inc

Type: Company
Name: Gilead Sciences Inc
First reported 23 hours ago - Updated 44 mins ago - 47 reports

Controversial hepatitis C drug drives up Gilead shares

The day after Gilead revealed that its costly hepatitis C drug had generated $2.3 billion in worldwide sales in just three months, its stock rose about 3 percent to $75.25 a share mid-day Wednesday. The jump jolted the Foster City company’s stock out ... [Published San Francisco Chronicle - 16 mins ago]
First reported 5 hours ago - Updated 1 hour ago - 3 reports

MARKET SNAPSHOT: U.S. Stocks Drift Lower

By Anora Mahmudova, MarketWatchNEW YORK (MarketWatch) -- U.S. stocks drifted lower in a choppy trading session Wednesday, putting the S&P 500 and Nasdaq Composite on track to end their six-day winning streaks.Investors also focused on a batch of mixed ... [Published 4 Traders - 1 hour ago]
First reported 10 hours ago - Updated 2 hours ago - 5 reports

Stocks: Lousy day on Wall Street

Wall Street's six-day win streak is in jeopardy on Wednesday as the bulls hit the pause button after disappointing housing data and mixed earnings reports.The Dow Jones industrial average and S&P 500 posted minor losses while the Nasdaq was solidly in ... [Published KETV.com - 2 hours ago]
First reported 22 hours ago - Updated 3 hours ago - 3 reports

Wednesday's most followed in U.S. including AT&T, Boeing, Delta Air, Yum Brands, Amgen, P&G, Dow Chemical, Gilead Sciences, EMC

11:45 am by AT&T Inc. (NYSE:T), the largest U.S. phone company, dropped 3.4 percent to $35.04 after reporting a decline in first-quarter profit, hurt by rising operating costs and income tax expenses.U.S. shares wavered between gains and losses as investors ... [Published Proactive Investors USA - 3 hours ago]
First reported 5 hours ago - Updated 3 hours ago - 2 reports

Big Biotech Is On The Move

By Bret Jensen :The dip in March and early April across the biotech sector looks like it was a gift to pick up some of the largest biotech companies' shares at a great discount at this point. Large cap biotechs look like they bottomed last week and some ... [Published BioPortfolio - 3 hours ago]
First reported 6 hours ago - Updated 3 hours ago - 4 reports

US STOCKS-Wall St edges down after six-day S&P rally; AT&T falls

* S&P 500, Nasdaq coming off six-day winning streak* AT&T falls after results, but Boeing rallies* Amgen drags biotech lower, but Gilead gains* Indexes down: Dow 0.1 pct, S&P 0.1 pct, Nasdaq 0.5 pct(Updates to open)NEW YORK, April 23 (Reuters) - U.S. ... [Published CNBC - 3 hours ago]
First reported 22 hours ago - Updated 5 hours ago - 3 reports

After Hours Gilead shares climb ATT Amgen shares fall

SAN FRANCISCO (MarketWatch) -- Gilead Sciences Inc., AT&T Inc. and Amgen Inc. were among the stocks actively trading Tuesday evening, with shares of Gilead climbing after handily beating Wall ... ... [Published Big News Network - 8 hours ago]
First reported 9 hours ago - Updated 6 hours ago - 2 reports

Gilead Sciences’ New Drug Application for Cobicistat for HIV Therapy Accepted by U.S. FDA

FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 21, 2014-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s refiling of two New Drug Applications (NDA) for cobicistat, a... ... [Published Drugs.com - 6 hours ago]
First reported Apr 22 2014 - Updated 7 hours ago - 6 reports

Gilead Sciences (GILD) Showing Support Near $71.25

Gilead Sciences Inc (GILD) presents a trading opportunity that offers a 7.22% return in just 59 days.A covered call on Gilead Sciences at the $75.00 level expiring on Jun. '14 offers an assigned return rate of 7.22% or 44.66% annualized. This trade offers ... [Published MarketIntelligenceCenter.com - 7 hours ago]
First reported Apr 21 2014 - Updated Apr 22 2014 - 6 reports

FDA Agrees to Review Cobicistat and Elvitegravir for HIV Therapy

Approval decisions expected in OctoberThe FDA has accepted the refiling of two new drug applications (NDAs) for cobicistat, a pharmacoenhancing or “boosting” agent that increases blood levels of the protease inhibitors atazanavir and darunavir to enable ... [Published P&T Community - Apr 22 2014]
First reported Apr 21 2014 - Updated Apr 22 2014 - 8 reports

Drugmaker Gilead's earnings could move markets

NEW YORK — A former biotech highflier. A hot new drug with a big price tag and huge earnings potential. And a must-see earnings report.It's Gilead Sciences, the drugmaker with the high-profile, blockbuster hepatitis C drug Sovaldi that's been in the news ... [Published USA Today - Apr 22 2014]
First reported Apr 21 2014 - Updated Apr 21 2014 - 2 reports

Why Gilead Sciences Is Heading To $80

By Wall Street Playbook :The healthcare industry is highly competitive. Nowhere else does the term " survival of the fittest " proves true. In this sector, companies survive by maintaining strong drug pipelines , which can be achieved in one of two ways. ... [Published BioPortfolio - Apr 21 2014]

Quotes

...to $12 from $13 as it expects the company to lose share as it struggles with content and faces increasing competition from smaller manufacturers. "We remain concerned with the outlook for the company going forward for a number of reasons" the brokerage said in a note
"Markets are waiting for a catalyst, and once the selling begins it may be quite drastic as there are no technical levels to support it. It will be partly a regression to mean, partly high valuations and partly because of risks in the global economy" he added
But there was a silver lining in the PMI report, according to analysis from Capital Economics, which said "while conditions in the manufacturing sector continue to weaken, they are no longer deteriorating as rapidly as before. It adds to growing evidence that, with infrastructure investment picking up, the recent slowdown in economic activity has begun to moderate."
Leerink analyst Dan Leonard wrote in a note Tuesday that the report "exceeded even what we would have considered a best-case scenario in the face of multiple new instrument launches" and lifted his price target to 180 from 160...

More Content

All (2148) | News (1855) | Reports (0) | Blogs (250) | Audio/Video (0) | Fact Sheets (7) | Press Releases (28)
sort by: Date | Relevance
Controversial hepatitis C drug drives up Gilead... [Published San Francisco Chronicle - 16 mins ago]
U.S. Stocks Decline as Tech Shares Sink Amid Co... [Published Washington Post - 32 mins ago]
MARKET PULSE-Hugoton, Zhone, Unisys, Sodastream... [Published London South East - 37 mins ago]
Earnings Roundup: What You Need to Know About G... [Published Motley Fool - 44 mins ago]
Fast and furious: Pricey Gilead hep C drug is f... [Published Business First of Buffalo - 1 hour ago]
How analysts got Gilead's earnings wrong [Published MSN Money - 1 hour ago]
Liver pill maker rakes in sales [Published LifeHealthPro - 1 hour ago]
Hottest Healthcare Stocks Now – GILD THC HCA CYH [Published InvestorPlace.com - 1 hour ago]
April 23 Sector Breadth and Intraday Trading... [Published Self Directed Investor - 1 hour ago]
MARKET SNAPSHOT: U.S. Stocks Drift Lower [Published 4 Traders - 1 hour ago]
Sovaldi NDA Review Marred By Manufacturing Comp... [Published Health News Daily - 2 hours ago]
Controversial hepatitis C drug drives up Gilead... [Published Tech Chronicles - 2 hours ago]
Nasdaq Lags at Midday [Published TD Ameritrade - 2 hours ago]
Stocks: Lousy day on Wall Street [Published KETV.com - 2 hours ago]
Midday movers: Facebook, Gilead Sciences & More [Published CNBC - 2 hours ago]
Strong Q1 Earnings at Gilead on Stellar Sovaldi... [Published Benzinga.com - 2 hours ago]
MARKET PULSE-Navigator, Xoom, Cree, Unisys, EMC... [Published Yahoo! UK and Ireland - 2 hours ago]
Payer revolt notwithstanding, Gilead's Sovaldi ... [Published FiercePharma - 2 hours ago]
Biogen revenue leaps 50% on blockbuster-level T... [Published FiercePharma - 2 hours ago]
Gilead Sciences: “Officially a Value Stock” [Published BARRONS.com Stocks To Watch Today - 3 hours ago]
Wednesday's most followed in U.S. including AT&... [Published Proactive Investors USA - 3 hours ago]
Big Biotech Is On The Move [Published BioPortfolio - 3 hours ago]
Gilead Sciences, Inc. Announces First Quarter 2... [Published BioSpace - 3 hours ago]
Solvaldi Too Expensive? Not To Patients—Gilead ... [Published BioSpace - 3 hours ago]
Biotech Continues Lagging [Published TD Ameritrade - 3 hours ago]
Gilead, Illumina Q1 Earnings Win Wall Street's ... [Published Investor's Business Daily - 3 hours ago]
US STOCKS-Wall St edges down after six-day S&P ... [Published CNBC - 3 hours ago]
Wednesday [Published San Francisco Chronicle - 3 hours ago]
Biotech ETF Loses Ground as Earnings Disappoint [Published BARRONS.com Focus on Funds - 3 hours ago]
Strong Q1 Earnings at Gilead on Stellar Sovaldi... [Published Yahoo! Finance - 4 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Controversial hepatitis C drug drives up Gilead... [Published Tech Chronicles - 2 hours ago]
The day after Gilead revealed that its costly hepatitis C drug had generated $2.3 billion in worldwide sales in just three months, its stock rose about 3 percent to $75.25 a share mid-day Wednesday. The jump jolted the Foster City company’s stock out ...
Gilead Sciences: “Officially a Value Stock” [Published BARRONS.com Stocks To Watch Today - 3 hours ago]
Earlier this month, RBC Capital Markets wondered whether Gilead Sciences (GILD) is actually a value stock. After last night’s earnings release, Piper Jaffray’s Joshua Schimmer and team say that’s now officially the case. Bloomberg They explain why Gilead’s ...
Biotech ETF Loses Ground as Earnings Disappoint [Published BARRONS.com Focus on Funds - 3 hours ago]
Fantastic earnings from Gilead Sciences (GILD) weren’t enough to keep a closely watched biotech ETF out of the red. The iShares Nasdaq Biotechnology ETF (IBB) fell almost 1.9% to $230.30 during morning market action, giving up gains from Tuesday’s after-hours ...
The $84,000 Cure [Published The Daily Dish | By Andrew Sullivan - 4 hours ago]
Earlier this month, Polly Mosendz covered the debate over Hepatitis C drug Sovaldi: [I]nsurers cannot stand this life saving, revolutionary medication. That’s because it runs $1,000 a day and  the average patient requires a 12-week treatment of Sovaldi. ...
Gilead's Hepatitis C Drug Solvaldi Delivers Hea... [Published TheStreet.com - YouTube - 4 hours ago]
<a style="font-size: 15px; font-weight: bold;font-decoration: none;" href="http://www.youtube.com/watch?v=9egtbr_YPPQ&feature=youtube_gdata"&gt;Gilead's Hepatitis C Drug Solvaldi Delivers Healthy Earnings Gilead delivered healthy earnings as a result ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Financial Release Dates -- Research on Gilead S... [Published Financial Services - Apr 14 2014]
Priority Reviews, Preliminary Earnings Releases... [Published Financial Services - Apr 11 2014]
Clinical Trial Results Presentation and Publica... [Published Financial Services - Apr 09 2014]
Senior Notes Conversions, FDA Drug Approvals, A... [Published Financial Services - Apr 03 2014]
Pending Applications, Closed Public Offering, J... [Published Financial Services - Apr 01 2014]
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.